12
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Inherited Mutations in Women with Ovarian Carcinoma

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Importance

          Germline mutations in BRCA1 and BRCA2 are relatively common in women with ovarian, fallopian tube, and peritoneal carcinoma (OC) causing a greatly increased lifetime risk of these cancers, but the frequency and relevance of inherited mutations in other genes is less well characterized.

          Objective

          To determine the frequency and importance of germline mutations in cancer-associated genes in OC.

          Design

          Subjects were ascertained from two phase III clinical trials in newly diagnosed advanced stage OC (GOG 218 and GOG 262), and a university-based gynecologic oncology tissue bank. Germline DNA was sequenced from women with OC using the targeted capture and multiplex sequencing assay BROCA.

          Setting

          Referral centers participating in NRG Oncology studies, and a University-based gynecologic oncology practice (UW).

          Participants

          The study population was 1915 women with OC with available germline DNA, unselected for age or family history, enrolled at the time of OC diagnosis (GOG 218, N=788; GOG 262, N=557; UW, N=570).

          Main Outcomes and Measures

          Mutation frequencies in OC were compared to the NHLBI GO Exome Sequencing Project (ESP) and the Exome Aggregation Consortium (ExAC). Clinical characteristics and survival were assessed by mutation status.

          Results

          Of 1915 subjects, 280 (15%) had mutations in BRCA1 (182), or BRCA2 (98) and 8 (0.4%) had mutations in DNA mismatch repair (MMR) genes. Mutations in BRIP1 (26), RAD51C (11), RAD51D (11), PALB2 (12) and BARD1 (4), were significantly more common in OC patients than in the ESP or ExAC, and in total were present in 3.3% of patients. Race, histologic subtype, and disease site were not predictive of mutation frequency. Mutation status affected survival, in particular for BRCA2 mutation carriers with HR 0.60 (95% CI 0.45 – 0.79, p<0.001) for progression-free survival, and HR 0.39 (95% CI 0.25 – 0.60, p<0.001) for overall survival in the GOG patients.

          Conclusions and Relevance

          In total, 347/1915 (18%) OC patients carried pathogenic germline mutations in genes associated with OC risk. PALB2 and BARD1 are suspected OC genes and together with established OC genes ( BRCA1, BRCA2, BRIP1, RAD51C, RAD51D, MSH2, MLH1, PMS2, and MSH6) bring the total number of genes suspected to cause hereditary OC to 11.

          Related collections

          Author and article information

          Journal
          101652861
          43608
          JAMA Oncol
          JAMA Oncol
          JAMA oncology
          2374-2437
          2374-2445
          19 April 2016
          1 April 2016
          01 April 2017
          : 2
          : 4
          : 482-490
          Affiliations
          [1 ]Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington, Seattle, WA
          [2 ]The NRG Oncology Statistical and Data Center, Roswell Park Cancer Center Institute, Buffalo, NY
          [3 ]Division of Medical Genetics, Department of Medicine, University of Washington, Seattle, WA
          [4 ]Department of Genome Sciences, University of Washington, Seattle, WA
          [5 ]Division of Gynecologic Oncology, University of Pennsylvania, Philadelphia, PA
          [6 ]Division of Gynecologic Oncology, Sutter Health California Pacific Medical Center, San Francisco, CA
          [7 ]Division of Gynecologic Oncology, University of Colorado, Denver, CO
          [8 ]Division of Gynecologic Oncology, University of Oklahoma, Oklahoma City, OK
          [9 ]Division of Gynecologic Oncology, Women and Infants Hospital, Providence, RI
          [10 ]Department of Pathology and Laboratory Medicine, The Research Institute at Nationwide Children’s Hospital, Columbus, OH
          [11 ]Massachusetts General Hospital, Department of Medicine, Harvard Medical School, Boston, MA
          Author notes
          Corresponding author: Barbara Norquist, MD, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington, Seattle, WA, Phone: 206-543-3669, Fax: 206-543-3915, bnorquis@ 123456uw.edu
          [*]

          Dr. Swisher and Dr. Birrer contributed equally to this project and are considered co-senior authors

          Article
          PMC4845939 PMC4845939 4845939 nihpa778753
          10.1001/jamaoncol.2015.5495
          4845939
          26720728
          7f1a157b-7b94-4909-93eb-d5cd0b85146e
          History
          Categories
          Article

          Comments

          Comment on this article